No. Retatrutide is not FDA approved, and it isn't approved anywhere else either. As of October 21, 2026, Eli Lilly has reported five phase 3 trials and says it plans to submit retatrutide for US approval in the first quarter of 2027. FDA's review only starts after that submission, so an approval cannot come before 2027. Lilly says the drug is available only to people enrolled in its clinical trials.
Notice: This page summarizes public company and regulatory documents. It isn't medical advice and contains no dosing or use guidance. Research peptides are sold for in-vitro laboratory research only and are not for human or animal consumption.
Retatrutide approval status at a glance
| Question | Answer (October 21, 2026) | Source |
|---|---|---|
| FDA approved? | No | Lilly, August 12, 2026 |
| Approved in any country? | No: "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world" | Lilly, August 12, 2026 |
| Submitted to FDA? | Not yet. Planned for Q1 2027 | Lilly, July 23, 2026 |
| Who can get it? | Only participants in Lilly-sponsored clinical trials | Lilly explainer, updated September 2026 |
| Can pharmacies compound it? | No | FDA GLP-1 page, October 1, 2026 |
| Brand name? | None yet. It is still known by its code, LY3437943 | Lilly |
Timeline: from phase 2 to the planned FDA filing
| Date | Event | Source |
|---|---|---|
| June 2023 | Phase 2 results published in NEJM: -24.2% body weight at 48 weeks in the highest dose group vs -2.1% on placebo | NEJM |
| December 11, 2025 | TRIUMPH-4 (obesity with knee osteoarthritis) results announced | Lilly |
| May 21, 2026 | TRIUMPH-1 (2,339 people without diabetes): -19.0% to -28.3% body weight at 80 weeks vs -2.2% placebo | Lilly |
| June 6, 2026 | TRANSCEND-T2D-1 (type 2 diabetes) results, published in The Lancet | Lilly |
| July 23, 2026 | TRIUMPH-2 and TRIUMPH-3 results; Lilly says it plans to submit for US approval in Q1 2027 | Lilly |
| August 12, 2026 | Lilly files six lawsuits against US sellers of "black-market" retatrutide and says no retatrutide medicine is approved anywhere | Lilly |
| August 24, 2026 | FDA warning letter to Peptide Partners names a "GLP-3 Reta" product as retatrutide | FDA |
| September 30, 2026 | Phase 3 data presented at EASD in Milan | Lilly |
| Q1 2027 (planned) | Lilly's US submission | Lilly, July 23, 2026 |
Trial details, side effects and the mechanism are covered in what is retatrutide and retatrutide side effects.
What happens after Lilly files
- FDA decides whether to accept the application for review, normally within 60 days of receiving it.
- FDA reviews it. Under FDA's user-fee goals, a standard review of a new molecular entity aims for a decision about 10 months after the 60-day filing date, and a priority review about 6 months after it (FDA PDUFA goals). Lilly hasn't said whether it will seek priority review.
- FDA approves, asks for more data, or rejects it. Only an approval would put a retatrutide brand on the US market.
So the earliest realistic decision falls in late 2027 if Lilly files in Q1 2027 and the review runs on schedule. Websites quoting an exact approval month are estimating; FDA has published no date.
What this means for "research" retatrutide
- It is not the trial drug. A vial sold online as research retatrutide (often labeled "GLP-3," "GLP-3 R" or "RT") is not made under Lilly's drug controls, and its identity and amount depend entirely on the seller.
- FDA is enforcing against it. FDA says it has warned companies that label unapproved GLP-1 drugs "for research purposes" or "not for human consumption" (FDA).
- Lilly is suing sellers. Eli Lilly has sued 11 retatrutide sellers since August 2026, including online peptide vendors; see every Eli Lilly peptide lawsuit.
- Check the paperwork. If you buy it as a laboratory reference material, insist on a lot-matched COA with mass-spec identity from a lab you can verify. See how to read a peptide COA and how to verify a Janoshik report.
- Compare sellers on testing, not price alone. Our retatrutide vendor ranking and retatrutide price index list who publishes COAs.
Sources are linked inline and were checked October 21, 2026. We update this page when Lilly files with FDA or FDA acts.
